AEterna Zentaris (AEZS) Receives Price Target

AEterna Zentaris (AEZS) : Average target price received by AEterna Zentaris (AEZS) is $11 with an expected standard deviation of $0.82. The most aggressive target on the stock is $12, whereas the most downbeat target is $10. 4 financial analysts are currently covering the stock.

AEterna Zentaris (AEZS) : The consensus on AEterna Zentaris (AEZS) based on 4 analyst recommendation on the company stock is 1.25, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future.


AEterna Zentaris (NASDAQ:AEZS): The stock opened at $3.66 on Thursday but the bulls could not build on the opening and the stock topped out at $3.73 for the day. The stock traded down to $3.52 during the day, due to lack of any buying support eventually closed down at $3.56 with a loss of -1.39% for the day. The stock had closed at $3.61 on the previous day. The total traded volume was 75,632 shares.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and womens health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.